Entity Details

Primary name APOA1_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP02647
EntryNameAPOA1_HUMAN
FullNameApolipoprotein A-I
TaxID9606
Evidenceevidence at protein level
Length267
SequenceStatuscomplete
DateCreated1986-07-21
DateModified2021-06-02

Ontological Relatives

GenesAPOA1

GO terms

Show/Hide Table
GOName
GO:0005543 phospholipid binding
GO:0005615 extracellular space
GO:0005886 plasma membrane
GO:0008203 cholesterol metabolic process
GO:0010903 negative regulation of very-low-density lipoprotein particle remodeling
GO:0014012 peripheral nervous system axon regeneration
GO:0019222 regulation of metabolic process
GO:0030300 regulation of intestinal cholesterol absorption
GO:0034115 negative regulation of heterotypic cell-cell adhesion
GO:0034191 apolipoprotein A-I receptor binding
GO:0034362 low-density lipoprotein particle
GO:0034371 chylomicron remodeling
GO:0034384 high-density lipoprotein particle clearance
GO:0034774 secretory granule lumen
GO:0050766 positive regulation of phagocytosis
GO:0050919 negative chemotaxis
GO:0051180 vitamin transport
GO:0060192 negative regulation of lipase activity
GO:0060761 negative regulation of response to cytokine stimulus
GO:0070062 extracellular exosome
GO:0070328 triglyceride homeostasis
GO:0072562 blood microparticle
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading
GO:1902995 positive regulation of phospholipid efflux
GO:1990000 amyloid fibril formation
GO:0002576 platelet degranulation
GO:0007186 G protein-coupled receptor signaling pathway
GO:0007229 integrin-mediated signaling pathway
GO:0009986 cell surface
GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway
GO:0010875 positive regulation of cholesterol efflux
GO:0010898 positive regulation of triglyceride catabolic process
GO:0018158 protein oxidation
GO:0019899 enzyme binding
GO:0019915 lipid storage
GO:0031410 cytoplasmic vesicle
GO:0032489 regulation of Cdc42 protein signal transduction
GO:0033344 cholesterol efflux
GO:0033700 phospholipid efflux
GO:0034365 discoidal high-density lipoprotein particle
GO:0034372 very-low-density lipoprotein particle remodeling
GO:0034375 high-density lipoprotein particle remodeling
GO:0035025 positive regulation of Rho protein signal transduction
GO:0042157 lipoprotein metabolic process
GO:0042632 cholesterol homeostasis
GO:0045499 chemorepellent activity
GO:0046470 phosphatidylcholine metabolic process
GO:0046889 positive regulation of lipid biosynthetic process
GO:0050728 negative regulation of inflammatory response
GO:0051006 positive regulation of lipoprotein lipase activity
GO:0060228 phosphatidylcholine-sterol O-acyltransferase activator activity
GO:0060354 negative regulation of cell adhesion molecule production
GO:0062023 collagen-containing extracellular matrix
GO:0120020 cholesterol transfer activity
GO:1903561 extracellular vesicle
GO:0001932 regulation of protein phosphorylation
GO:0001935 endothelial cell proliferation
GO:0005788 endoplasmic reticulum lumen
GO:0005829 cytosol
GO:0006869 lipid transport
GO:0006898 receptor-mediated endocytosis
GO:0007584 response to nutrient
GO:0030139 endocytic vesicle
GO:0030325 adrenal gland development
GO:0031072 heat shock protein binding
GO:0034190 apolipoprotein receptor binding
GO:0034361 very-low-density lipoprotein particle
GO:0034363 intermediate-density lipoprotein particle
GO:0042493 response to drug
GO:0042627 chylomicron
GO:0042802 identical protein binding
GO:0043534 blood vessel endothelial cell migration
GO:0043627 response to estrogen
GO:0043687 post-translational protein modification
GO:0044267 cellular protein metabolic process
GO:0051345 positive regulation of hydrolase activity
GO:0051496 positive regulation of stress fiber assembly
GO:0055102 lipase inhibitor activity
GO:0070653 high-density lipoprotein particle receptor binding
GO:0071682 endocytic vesicle lumen
GO:0001523 retinoid metabolic process
GO:0001540 amyloid-beta binding
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0005102 signaling receptor binding
GO:0005576 extracellular region
GO:0005634 nucleus
GO:0005769 early endosome
GO:0006656 phosphatidylcholine biosynthetic process
GO:0006695 cholesterol biosynthetic process
GO:0008035 high-density lipoprotein particle binding
GO:0008211 glucocorticoid metabolic process
GO:0010873 positive regulation of cholesterol esterification
GO:0015485 cholesterol binding
GO:0018206 peptidyl-methionine modification
GO:0030301 cholesterol transport
GO:0031100 animal organ regeneration
GO:0031210 phosphatidylcholine binding
GO:0032691 negative regulation of interleukin-1 beta production
GO:0034364 high-density lipoprotein particle
GO:0034366 spherical high-density lipoprotein particle
GO:0034378 chylomicron assembly
GO:0034380 high-density lipoprotein particle assembly
GO:0042158 lipoprotein biosynthetic process
GO:0043691 reverse cholesterol transport
GO:0045723 positive regulation of fatty acid biosynthetic process
GO:0050821 protein stabilization
GO:0055091 phospholipid homeostasis
GO:0070508 cholesterol import

Subcellular Location

Show/Hide Table
Subcellular Location
Secreted

Domains

Show/Hide Table
DomainNameCategoryType
IPR000074 Apolipoprotein A/EFamilyFamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
618463 OMIMHypoalphalipoproteinemia, primary, 2 (FHA2)A rare disorder of lipoprotein metabolism, biochemically characterized by complete or partial apoA-I deficiency and mild to severe reduction of serum high-density lipoprotein cholesterol (HDL-C). Severe hypoalphalipoproteinemia characterized by undetectable levels of apoA-I is an autosomal recessive condition, generally associated with markedly increased atherosclerotic cardiovascular disease, xanthomas and corneal opacities. Mild hypoalphalipoproteinemia characterized by half the normal plasma apoA-I and HDL-C levels is inherited as an autosomal dominant trait, may be associated with xanthomas and corneal opacities, but most patients do not have increased cardiovascular risk. The disease is caused by variants affecting the gene represented in this entry.
105200 OMIMAmyloidosis 8 (AMYL8)A form of hereditary generalized amyloidosis. Clinical features include extensive visceral amyloid deposits, renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. There is no involvement of the nervous system. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB01593 ZincDrugbanksmall molecule
DB09130 CopperDrugbanksmall molecule
DB14487 Zinc acetateDrugbanksmall molecule
DB14533 Zinc chlorideDrugbanksmall molecule
DB14548 Zinc sulfate, unspecified formDrugbanksmall molecule

Interactions

51 interactions

InteractorPartnerSourcesPublicationsLink
APOA1_HUMANMA7D1_HUMANBioGRID, HPRD, IntAct16169070 details
APOA1_HUMANTR10C_HUMANBioGRID, HPRD, IntAct16169070 details
APOA1_HUMANTOM20_HUMANBioGRID, HPRD, IntAct16169070 details
APOA1_HUMANPIMT_HUMANHPRD, IntAct16169070 details
APOA1_HUMANA4_HUMANBioGRID, IntAct11297421 21832049 32814053 7802646 details
APOA1_HUMANAPOC1_HUMANBioGRID, IntAct11991719 15174051 details
APOA1_HUMANCLC4G_HUMANBioGRID, IntAct18624398 details
APOA1_HUMANHPT_HUMANBioGRID, MINT15533931 19758344 24981860 details
APOA1_HUMANFBLN1_HUMANBioGRID, IntAct21988832 details
APOA1_HUMANRPA12_HUMANBioGRID, IntAct21988832 details
APOA1_HUMANAKT2_HUMANBioGRID, IntAct21988832 details
APOA1_HUMANJAK3_HUMANBioGRID, IntAct21988832 details
APOA1_HUMANOSTP_HUMANBioGRID, IntAct21988832 details
APOA1_HUMANMK06_HUMANBioGRID, IntAct, MINT21900206 28514442 details
APOA1_HUMANAPOA1_HUMANBioGRID, DIP, HPRD, IntAct, MINT11744719 15174051 17676061 18719128 20133843 20884842 22184756 22609356 24316228 24702826 8810909 9003180 9200714 9356442 details
APOA1_HUMANSCRB1_HUMANbhf-ucl, BioGRID, HPRD1076467 10764676 details
APOA1_HUMANABCA1_HUMANbhf-ucl, BioGRID, HPRD, IntAct12084722 27017521 30458687 details
APOA1_HUMANLCAT_HUMANbhf-ucl, BioGRID, DIP, HPRD10026251 10222237 15654758 1587806 1644835 17676061 3104518 4335615 details
APOA1_HUMANCKLF5_HUMANBioGRID, IntAct25416956 25910212 32296183 details
APOA1_HUMANBRAP_HUMANBioGRID, IntAct25820252 details
APOA1_HUMANLAMP2_HUMANIntAct32814053 details
APOA1_HUMANSHLB1_HUMANIntAct32814053 details
APOA1_HUMANPDE1A_HUMANBioGRID, HPRD11991719 details
APOA1_HUMANPLTP_HUMANBioGRID, HPRD11854286 9469594 details
APOA1_HUMANPHLD_HUMANBioGRID, HPRD11254757 details
APOA1_HUMANSAA2_HUMANBioGRID11991719 details
APOA1_HUMANNNRE_HUMANBioGRID, HPRD11991719 details
APOA1_HUMANABCAD_HUMANBioGRID11162594 details
APOA1_HUMANVKOR1_HUMANBioGRID21103663 details
APOA1_HUMANAPOA2_HUMANBioGRID10722751 24981860 3104518 details
APOA1_HUMANNDRG1_HUMANBioGRID15922294 details
APOA1_HUMANTREM2_HUMANBioGRID27477018 details
APOA1_HUMANHS90A_HUMANBioGRID31273033 details
APOA1_HUMANTTHY_HUMANBioGRID, HPRD, IntAct10627502 15174051 details
APOA1_HUMANSYUA_HUMANBioGRID, IntAct28887769 31270237 details
APOA1_HUMANC1QBP_HUMANIntAct28565870 details
APOA1_HUMANAPOB_HUMANBioGRID, HPRD, IntAct19164805 28183703 7592581 details
APOA1_HUMANAPOL1_HUMANBioGRID9325276 details
APOA1_HUMANAPOF_HUMANBioGRID, HPRD6816269 details
APOA1_HUMANLBP_HUMANBioGRID, HPRD8663389 details
APOA1_HUMANCD40L_HUMANBioGRID10085035 details
APOA1_HUMANTERA_HUMANBioGRID19164805 details
APOA1_HUMANDGAT1_HUMANBioGRID3104518 details
APOA1_HUMANAPOD_HUMANBioGRID3104518 details
APOA1_HUMANATP4A_HUMANBioGRID17255364 details
APOA1_HUMANU2AF2_HUMANBioGRID26641092 details
APOA1_HUMANCETP_HUMANHPRD9305883 details
APOA1_HUMANPON1_HUMANHPRD16128586 details
APOA1_HUMANFHR1_HUMANHPRD8663389 details
APOA1_HUMANATPB_HUMANHPRD2687158 details
APOA1_HUMANHPTR_HUMANHPRD10085035 details